Drug Profile
Amikacin liposomal - Gilead Sciences
Alternative Names: MiKasome®Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator NeXstar Pharmaceuticals
- Developer Gilead Sciences
- Class Aminoglycosides; Anti-infectives; Antibacterials; Small molecules
- Mechanism of Action Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cystic fibrosis-associated respiratory tract infections; Mycobacterium avium complex infections; Nosocomial infections; Pseudomonal infections; Tuberculosis; Urinary tract infections
Most Recent Events
- 09 Oct 2000 Discontinued-I for Mycobacterium avium complex infections in USA (Parenteral)
- 09 Oct 2000 Discontinued-I for Tuberculosis in USA (Parenteral)
- 09 Oct 2000 Discontinued-II for Cystic fibrosis-associated respiratory tract infections in USA (Parenteral)